TAXIS Pharmaceuticals, Inc.
June 23, 2026
Theater 4
Type: Company Presentation
Focus Area:
Infectious Disease and Vaccines
TAXIS develops drugs to kill bacterial Superbugs. We are breaking the mold of antibiotic drug development, which has only yielded, over the past few decades, incremental innovations on old themes. Our transformational technologies will revolutionize antimicrobial resistant disease control.
Company HQ City:
Miami
Company HQ State:
Florida
Company HQ Country:
United States
Year Founded:
2010
Lead Product in Development:
TAXIS has 3 unique technologies - the most advanced is an oral, anti-MRSA drug that completed successfully Phase I (first in human) study.
CEO
Gregory G Mario
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
NA - we own all of it, with a deep and broad patent portfolio
When you expect your next catalyst update?
2027
What is your next catalyst (value inflection) update?
By 2027, TAXIS will have 3 drugs in the clinic, including one 1 with definitive PII data
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}